Worth Watching Stock for Traders: Neurocrine Biosciences (NASDAQ:NBIX)

Worth Watching Stock for Traders: Neurocrine Biosciences (NASDAQ:NBIX)

Neurocrine Biosciences (NASDAQ:NBIX) changed 0.65% to recent value of $90.92. The stock transacted 485283 shares during most recent day however it has an average volume of 675.8K shares. It spotted trading -21.94% off 52-week high price. On the other end, the stock has been noted 40.48% away from the low price over the last 52-weeks.

On Oct. 14, 2019, Neurocrine Biosciences (NASDAQ:NBIX) revealed that it will report third quarter financial results after the NASDAQ market closes on Monday, November 4, 2019. Neurocrine will then host a conference call and webcast to discuss its financial results and provide a Company update that day at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).

Participants can access the live conference call by dialing 800-894-5910 (US) or 785-424-1052 (International) using the conference ID: NBIX. The webcast can also be accessed on Neurocrine’s website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

About Neurocrine Biosciences

Neurocrine Biosciences (Nasdaq: NBIX) is a neuroscience-focused, biopharmaceutical company with more than 25 years of experience discovering and developing life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia and endometriosis* and clinical development programs in multiple therapeutic areas including Parkinson’s disease, congenital adrenal hyperplasia, uterine fibroids* and polycystic ovary syndrome*. Headquartered in San Diego, Neurocrine Biosciences specializes in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems.

NBIX has a gross margin of 99.00% and an operating margin of 1.60% while its profit margin remained 3.00% for the last 12 months. Its earnings per share (EPS) expected to touch remained 113.70% for this year.

The company has 91.39M of outstanding shares and 90.38M shares were floated in the market. According to the most recent quarter its current ratio was 7.4 that represents company’s ability to meet its current financial obligations. The price moved ahead of -2.38% from the mean of 20 days, -4.56% from mean of 50 days SMA and performed 5.36% from mean of 200 days price. Company’s performance for the week was 3.58%, -5.69% for month and YTD performance remained 27.32%.

Posted in

William Payton

William Payton possesses over 7 years of investment experience, an M.B.A. from California State University, and is also certified in Risk Management Assurance. He is a self-taught investor and follows the value investing approach to picking stocks. William has exploited those observations and developed investment tactics within a fundamentally sound long-term investment strategy. He currently covers Earnings News category for our site. William is a Certified Internal Auditor, Data Miner, and author with a career broadly spanning over multiple business areas. Address: 4831 Elk Street, Irvine, California, USA Phone number: 949-757-9251 Email: William@surveypaid.info 

Leave a Reply

Your email address will not be published. Required fields are marked *